Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-007 first-line MK-1084 plus subcutaneous pembrolizumab versus pembrolizumab plus platinum/pemetrexed in KRAS G12C-mutant nonsquamous NSCLC
MOH_2025-10-28_015414Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of calderasib, pembrolizumab, pemetrexed, carboplatin, cisplatin and 1 more in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on MOH_2025-10-28_015414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-28_015414.